Lewis Acid Mediated Hetero-Michael Addition Reactions
484 493
7.26 7.33 (m, 5H; Ar-H), 9.39 ppm (br, 1H; NH); 13C NMR (100 MHz,
CDCl3): d=10.8, 25.4 (CH3), 28.3, 42.3 (CH2), 50.2 (CH), 67.0 (CH2),
128.3, 128.5, 128.9 (Ar-C), 136.9 (ipso-Ar-C), 156.5, 172.7, 172.8 ppm (C=
O); IR (neat, film): n˜ =3317, 3144, 2976, 1734, 1709, 1686, 1534,
1245 cmÀ1; HRMS [+ESI]: calcd for [C15H20N2O4Na]+ : 315.1321, found:
315.1313 [M+Na]+.
(100 MHz, CD3CN): d=8.3, 26.2 (CH3), 37.6, 53.2 (CH2), 54.2 (CH),
208.3 ppm (C=O); IR (neat, film): n˜ =2961, 1726, 1393, 1250, 1066 cmÀ1
;
HRMS [EI, 70 eV] calcd for: [C6H11ClO]+ : 134.0498; found: 134.0494
[M]+.
1-(Benzyloxy)pentan-3-one (16a): Compound 16a was prepared accord-
ing to GP1 (Tf2NH, 1.0 mmol scale, 12 h) and was obtained as a colour-
less oil (151 mg, 79%). Rf 0.44 (CH2Cl2/acetone 30:1). 1H NMR
(500 MHz, CDCl3): d=1.08 (t, J=7.4 Hz, 3H; CH2CH3), 2.49 (q, J=
7.4 Hz, 2H; CH2CH3), 2.71 (t, J=6.3 Hz, 2H; C(O)CH2), 3.77 (t, J=
6.3 Hz, 2H; OCH2), 4.53 (s, 2H; OCH2), 7.30 7.41 ppm (m, 5H; Ar-H);
13C NMR (100 MHz, CDCl3): d=7.4 (CH3), 36.4, 42.3, 65.2, 73.0 (CH2),
127.4, 127.5, 128.2 (Ar-C), 138.0 (ipso-Ar-C), 209.6 ppm (C=O); IR (neat,
film): n˜ =2975, 2871, 1711, 1454, 1364, 1090, 735 cmÀ1; HRMS [EI, 70 eV]
calcd for: [C12H16O2]+ : 192.1150; found: 192.1155 [M]+.
Compound 9 was isolated as a side product in the synthesis of 5b accord-
ing to GP1 ([Pd(CH3CN)4(BF4)2], 1.0 mmol scale) as a colourless solid
(17 mg, 5%). Samples from several runs were combined and crystals suit-
able for X-ray crystallography were obtained from pentane/diethyl ether.
Rf 0.35 (PE/diethyl ether 1:3); M.p. 136 1378C; 1H NMR (400 MHz,
CDCl3): d=1.42 1.69 (m, 7H; CH2, CH), 1.80 1.86 (m, 1H; CHH), 1.90
2.01 (m, 4H; CH2, CH), 2.20 2.28 (m, 1H; CH), 2.34 (t, J=6.2 Hz, 1H;
C(O)CH), 2.71 (m, 1H; C(O)CH), 4.92 (br, 1H; NH), 5.05 (s, 2H;
OCH2), 7.28 7.36 ppm (m, 5H; Ar-H); 13C NMR (100 MHz, CDCl3): d=
20.9, 23.5, 23.5, 23.7 (CH2), 28.2, 35.8 (CH), 36.1 (CH2), 37.1, 51.5, 53.4
(CH), 56.7 (Cquart), 66.9 (CH2), 128.6, 128.7, 129.0 (Ar-C), 136.7 (ipso-Ar-
C), 155.8, 218.9 ppm (C=O); IR (neat, film): n˜ =3304, 3248, 2924, 2855,
3-(2-Oxo-oxazolidin-3-yl)-1-phenylpentan-1-one (24): Compound 24 was
prepared according to GP1 (Tf2NH, 1.0 mmol scale, 1 h) and was isolated
as a colourless solid (232 mg, 94%). Rf 0.17 (diethyl ether); m.p. 48
1
508C; H NMR (400 MHz, CDCl3): d=0.92 (t, J=7.4 Hz, 3H; CH2CH3),
1733, 1690, 1535, 1262 cmÀ1; HRMS [+ESI]: calcd for [C20H23NO3Na]+
348.1576; found: 348.1581 [M+Na]+).
:
1.61 1.78 (m, 2H; CH2CH3), 3.12 (dd, J=5.7, 16.2 Hz, 1H; C(O)CHH),
3.33 (dd, J=7.9, 16.2 Hz, 1H; C(O)CHH), 3.57 (dt, J=2.3, 7.9 Hz, 2H;
NCH2), 4.07 (m, 1H; NCH), 4.21 (t, J=7.9 Hz, 2H; OCH2), 7.42 (dd, J=
7.5, 7.9 Hz, 2H; m-Ar-H), 7.53 (t, J=7.5 Hz, 1H; p-Ar-H), 7.91 ppm (d,
J=7.9 Hz, 2H; o-Ar-H); 13C NMR (100 MHz, CDCl3): d=11.2 (CH3),
25.6, 41.4, 43.0 (CH2), 52.9 (CH), 62.4 (CH2), 128.4, 129.0, 133.7 (Ar-C),
136.9 (ipso-Ar-C), 158.1, 198.3 (C=O); IR (neat, film): n˜ =2963, 2910,
(Z)-4-(2,2,2-Trideuteroacetylamido)pent-2-en-2-olato palladium(ii) com-
plexes (10): The complexes were prepared by dissolving pent-3-en-2-one
(2d) (21 mL, 18 mg, 0.21 mmol) and [Pd(CH3CN)4(BF4)2] (100 mg,
0.210 mmol) in CD3CN (0.75 mL). The starting enone was completely
consumed within 2 h and the products were analysed in situ (70:30 mix-
ture). Major species: 1H NMR (400 MHz, CD3CN): d=1.66 (d, J=
6.7 Hz, 3H; CHCH3), 1.79 (s, 3H;=CCH3), 4.00 (m, 1H; NCH),
4.79 ppm (m, 1H; C=CH); 13C NMR (100 MHz, CD3CN): d=15.9, 23.0
(CH3), 53.7 (CH), 101.1 (=CH), 144.8 (=Cquart), 166.9 ppm (C=O);[57]
Minor species: 1H NMR (400 MHz, CD3CN): d=1.35 (d, J=6.6 Hz, 3H;
CHCH3), 1.89 (s, 3H;=CCH3), 4.28 (m, 1H; NCH), 5.20 ppm (m, 1H;
C=CH); 13C NMR (100 MHz, CD3CN): d=16.3, 21.5 (CH3), 43.0 (CH),
102.7 (=CH), 145.4 (=Cquart), 171.7 ppm (C=O);[57] IR (mixture, in
CD3CN): n˜ =1734, 1647, 1524, 1197 cmÀ1; HRMS [+ESI]: calcd for
[C7H9D3NO2Pd]+ : 251.0091; found: 251.0089 [M+H]+.[58]
1736, 1686, 1425, 1226, 1057, 756 cmÀ1
; HRMS [+ESI] calcd for
[C14H17NO3Na]+ : 270.1106; found: 270.1098 [M+Na]+.
3-[3-(Benzylideneamino)propionyl]-2-oxazolidinone N-oxide (25): Com-
pound 25 was prepared according to GP1 (Tf2NH (50%), in CH2Cl2,
10 h) and was obtained as a colourless solid (112 mg, 87%). Rf 0.05 (PE/
EtOAc 1:1); m.p. 169 1718C; 1H NMR (500 MHz, CD3CN): d=3.48 (t,
J=6.3 Hz, 2H; C(O)CH2), 3.90 (t, J=8.3 Hz, 2H; NCH2), 4.24 (t, J=
6.3 Hz, 2H; NCH2), 4.36 (t, J=8.3 Hz, 2H; OCH2), 7.42 7.48 (m, 3H; m-
Ar-H, p-Ar-H), 7.74 (s, 1H; N=CH), 8.22 8.24 ppm (m, 2H; o-Ar-H);
13C NMR (126 MHz, CDCl3): d=32.5, 42.4, 60.8, 62.8 (CH2), 128.5, 128.7,
130.6 (Ar-C), 130.6 (ipso-Ar-C), 136.3 (N=CH), 154.3, 170.9 ppm (C=
O); IR (neat, film): n˜ =2975, 1776, 1761, 1694, 1380, 1214, 1118,
755 cmÀ1; HRMS [+ESI] calcd for [C13H14N2O4Na]+ : 285.0851; found:
285.0858 [M+Na]+.
N-(1-Methyl-3-oxo-butyl)-2,2,2-trideuteroacetamide (11): Formic acid
(1.0 mL, 0.80 g, 18 mmol) was added to the solution described in the
preparation of the complexes 10. The mixture was stirred at 508C. After
2 h the initially dark orange solution became clear and Pd0 had precipi-
tated. The solid was filtered off, aqueous Na2CO3 (5 mL) was added and
the mixture was extracted with CH2Cl2 (3î10 mL). The combined organ-
ic phases were dried over Na2SO4 and filtered, and the solvent was re-
moved in vacuo. The product was obtained as a colourless oil (26 mg,
3-[3-(N-Methyl-N-phenylamino)propionyl]oxazolidin-2-one (26): Com-
pound 26 was prepared according to GP1 (Tf2NH, 12 h) and was ob-
tained as
a colourless oil (122 mg, 98%). Rf 0.29 (diethyl ether);
1H NMR (500 MHz, CDCl3) d=2.96 (s, 3H; NCH3), 3.20 (t, J=7.1 Hz,
2H; NCH2), 3.73 (t, J=7.1 Hz, 2H; C(O)CH2), 3.91 (t, J=8.3 Hz, 2H;
NCH2), 4.30 (t, J=8.3 Hz, 2H; OCH2), 6.70 (t, J=7.1 Hz, 1H; p-Ar-H),
6.78 (d, J=8.0 Hz, 2H; o-Ar-H), 7.22 ppm (dd, J=7.1, 8.0 Hz, 2H; m-Ar-
H); 13C NMR (126 MHz, CDCl3) d=32.6 (CH2), 38.2 (CH3), 42.5, 48.3,
62.1 (CH2), 112.6, 116.7, 129.2 (Ar-C), 149.0 (ipso-Ar-C), 153.8,
172.3 ppm (C=O); IR (neat, film): n˜ =2918, 1771, 1690, 1598, 1505, 1385,
1220, 1034 cmÀ1; HRMS [+ESI] calcd for [C13H16N2O3Na]+ : 271.1059;
found: 271.1062 [M+Na]+.
1
87%); H NMR (500 MHz, CDCl3): d=1.20 (d, J=6.3 Hz, 3H; CHCH3),
2.14 (s, 3H; C(O)CH3), 2.59 (dd, J=5.7, 16.8 Hz, 1H; C(O)CHH), 2.66
(dd, J=5.0, 16.8 Hz, 1H; C(O)CHH), 4.30 (m, 1H; NCH), 6.20 ppm (br,
1H; NH); 13C NMR (126 MHz, CDCl3): d=20.1, 30.6 (CH3), 41.9 (CH),
48.7 (CH2), 169.5, 208.2 ppm (C=O);[57] IR (neat, film): n˜ =3287, 3075,
2927, 1710, 1637, 1546, 1370, 729 cmÀ1; HRMS [EI, 70 eV] calcd for:
[C7H10D3NO2]+ : 146.1135; found: 146.1132 [M]+.
N-(1-Methyl-3-oxo-butyl)acetamide (H3-11): Compound H3-11 was pre-
pared in analogy to compound 11 with CH3CN as a solvent. The product
was obtained as a colourless oil (27 mg, 88%). 1H NMR (500 MHz,
CDCl3): d=1.21 (d, J=6.3 Hz, 3H; CHCH3), 1.92 (s, 3H; C(O)CH3),
2.14 (s, 3H; C(O)CH3), 2.60 (dd, J=5.7, 16.8 Hz, 1H; C(O)CHH), 2.67
(dd, J=5.0, 16.8 Hz, 1H; C(O)CHH), 4.30 (m, 1H; NCH), 6.14 ppm (br,
1H; NH); 13C NMR (126 MHz, CDCl3): d=20.2, 23.4, 30.6 (CH3), 41.9
(CH), 48.6 (CH2), 169.4, 208.2 ppm (C=O); IR (neat, film): n˜ =3287,
3084, 2924, 1710, 1648, 1547, 1370, 731 cmÀ1; HRMS [EI, 70 eV] calcd
for: [C7H13NO2]+ : 143.0946; found: 143.0947 [M]+.
3-(Phenylsulfanyl)cyclohexan-1-one (27): Compound 27 was prepared ac-
cording to GP1 (Tf2NH, in CHCl3, 2 h) and was obtained as a colourless
oil (99 mg, 96%). Rf 0.31 (PE/ether 1:1); 1H NMR (500 MHz, CDCl3):
d=1.70 1.75 (m, 2H; CH2), 2.12 2.17 (m, 2H; CH2), 2.29 2.40 (m, 3H;
C(O)CH2, C(O)CHH), 2.68 (dd, J=4.4, 14.3 Hz, 1H; C(O)CHH), 3.44
(m, 1H; SCH), 7.27 7.33 (m, 3H; m-Ar-H, p-Ar-H), 7.42 ppm (d, J=
5.7 Hz, 2H; o-Ar-H); 13C NMR (126 MHz, CDCl3): d=24.0, 31.2, 40.9
(CH2), 46.1 (CH), 47.8 (CH2), 127.8, 129.0 (Ar-C), 133.1 (ipso-Ar-C),
133.2 (Ar-C), 208.6 ppm (C=O); IR (neat, film): n˜ =3056, 2943, 1708,
1582, 1438, 1220, 1024, 739 cmÀ1; HRMS [+ESI] calcd for [C12H15OS]+
207.0844; found: 207.0848 [M+H]+.
:
5-Chlorohexan-3-one (12): Compound 12 was prepared by bubbling gas-
eous HCl through a solution of 2e (57 mL, 49 mg, 0.5 mmol) in CH3CN
(1 mL) for 10 min. The solvent was evaporated and preparative thin-
layer chromatography furnished a colourless oil (22 mg, 34%). The NMR
spectra of this compound and of stoichiometric mixtures of 2e and AlCl3,
TiCl4, ReCl5 in CD3CN were identical. Rf 0.50 (PE/diethyl ether 1:1);
1H NMR (400 MHz, CD3CN): d=0.96 (t, J=7.0 Hz, 3H; CH2CH3), 1.47
(d, J=6.6 Hz, 3H; CHCH3), 2.41 (q, J=7.0 Hz, 2H; CH2CH3), 2.75 (dd,
J=5.1, 17.1 Hz, 1H; C(O)CHH), 2.89 (dd, J=7.8, 17.1 Hz, 1H;
C(O)CHH), 4.45 ppm (ddq, J=5.1, 6.6, 7.8 Hz, 1H; CHCl); 13C NMR
3-[3-(Benzylsulfanyl)propionyl]oxazolidin-2-one (28): Compound 28 was
prepared according to GP1 (Tf2NH, in CH2Cl2, 2 h) and was obtained as
a colourless oil (124 mg, 93%). Rf 0.27 (ether); 1H NMR (500 MHz,
CDCl3): d=2.74 (t, J=7.0 Hz, 2H; SCH2), 3.20 (t, J=7.0 Hz, 2H;
C(O)CH2), 3.76 (s, 2H; Ar-CH2), 3.99 (t, J=8.3 Hz, 2H; NCH2), 4.38 (t,
J=8.3 Hz, 2H; OCH2), 7.24 7.36 ppm (m, 5H; Ar-H); 13C NMR
(126 MHz, CDCl3): d=25.6, 35.2, 36.3, 42.5, 62.2 (CH2), 127.0, 128.5,
128.9 (Ar-C), 138.2 (ipso-Ar-C), 153.5, 171.6 ppm (C=O); IR (neat, film):
491
Chem. Eur. J. 2004, 10, 484 493
¹ 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim